Discontinued — last reported Q1 '26
Merck & Co. Latin America — Sales increased by 2.3% to $874.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.4%, from $792.00M to $874.00M. Over 4 years (FY 2021 to FY 2025), Latin America — Sales shows an upward trend with a 11.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful product adoption or market expansion in the region, while a decrease may signal competitive pressure, regulatory hurdles, or adverse macroeconomic conditions.
This metric represents the total revenue generated from the sale of pharmaceutical products and services within the Lati...
Peers in the pharmaceutical industry typically report regional revenue to demonstrate geographic diversification and emerging market performance.
mrk_segment_latin_america_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $532.00M | $599.00M | $506.00M | $607.00M | $642.00M | $684.00M | $649.00M | $661.00M | $742.00M | $895.00M | $788.00M | $796.00M | $858.00M | $936.00M | $869.00M | $792.00M | $859.00M | $905.00M | $854.00M | $874.00M |
| QoQ Change | — | +12.6% | -15.5% | +20.0% | +5.8% | +6.5% | -5.1% | +1.8% | +12.3% | +20.6% | -12.0% | +1.0% | +7.8% | +9.1% | -7.2% | -8.9% | +8.5% | +5.4% | -5.6% | +2.3% |
| YoY Change | — | — | — | — | +20.7% | +14.2% | +28.3% | +8.9% | +15.6% | +30.8% | +21.4% | +20.4% | +15.6% | +4.6% | +10.3% | -0.5% | +0.1% | -3.3% | -1.7% | +10.4% |